-
CACA-GO | Professor Declan Murphy on Whether Pelvic Lymph Node Dissection for Prostate Cancer Is “Dead”
The 14th Shanghai Genitourinary Oncology Academic Conference and Annual Meeting of Chinese Anti-Cancer Association—Genitourinary Oncology Committee (CACA-GO) recently took place in Shanghai. The conference invited numerous internationally renowned experts in uro-oncology to deliver academic presentations and perform surgical demonstrations. Professor Declan Murphy from the Peter MacCallum Cancer Centre in Australia delivered a compelling talk titled…
-
AASLD 2024: Dr. Mingqin Lu’s Team Presents Study on Biomimetic Exosomes Loaded with Iridium Nanozyme for Acute Liver Failure Treatment
Acute liver failure (ALF) is a severe clinical syndrome characterized by the rapid deterioration of liver function, often accompanied by multi-organ failure. Given its complex mechanisms and limited treatment options,…
-
ESMO Asia 2024 | Professor Ming Cao on Bladder-Sparing Strategies Combining Local Surgery and Chemoradiotherapy for MIBC Patients
Radical cystectomy remains the standard treatment for muscle-invasive bladder cancer (MIBC), but many patients express a strong desire to preserve their bladder. To address this, various bladder-sparing strategies have been explored, including transurethral resection of bladder tumor (TURBT), partial cystectomy (PC), chemotherapy, radiotherapy, and surveillance. At the recent ESMO Asia Annual Meeting, Professor Ming Cao…
-
ESMO Asia 2024 | Professor Xuefeng Qiu Reviews Progress in Prostate Cancer Diagnosis and Treatment, Shares Research Achievements from Gulou Hospital
As 2024 draws to a close, the field of oncology celebrates the year’s grand finale with the ESMO ASIA Annual Meeting. The conference not only attracted top scholars and researchers from across Asia and the global oncology community but also showcased numerous breakthroughs in urologic oncology. On-site at the conference, Urology Frontier invited Professor Xuefeng…
-
ESMO Asia 2024 | Early Trials Show Favorable Benefit-Risk Profiles for Oral Small-Molecule PD-L1 Inhibitor
At the 2024 ESMO Asia Congress “Preferred Oral Presentations – Development and Precision Medicine” session, two oral immune checkpoint inhibitors (ICIs) for solid tumors demonstrated initial efficacy and manageable safety in early-phase trials. These results support further development of novel small-molecule PD-L1 inhibitors, which offer favorable benefit-risk profiles and better usability compared to antibody-based ICIs.
-
ESMO Asia 2024 | Professor Jordi Remon Masip Highlights Key Thoracic Oncology Studies
The thoracic oncology session at the 2024 ESMO Asia Annual Meeting featured prominent oral presentations, focusing on thymic tumors and non-small cell lung cancer (NSCLC). Key studies included the Phase II MARBLE trial (Abstract LBA8) evaluating atezolizumab combined with carboplatin/paclitaxel for metastatic or recurrent thymic carcinoma and the Phase II AL3810-202 trial (Abstract 6250) assessing…
-
ILCA 2024 | Professor Masatoshi Kudo Shares Insights on the Prognostic and Treatment-Guiding Value of ORR, DpR, and DoR in HCC Patients
Previous studies have demonstrated that short-term efficacy metrics, such as objective response rate (ORR), are associated with long-term survival outcomes, such as overall survival (OS), in targeted therapy for advanced hepatocellular carcinoma (HCC). At the 2024 International Liver Cancer Association (ILCA) Conference, Professor Masatoshi Kudo from Kinki University Faculty of Medicine in Japan presented exploratory…
-
ESMO Asia 2024 | Professor Wentao Fang Discusses Advances in Thymic Cancer Treatments
The 2024 European Society for Medical Oncology Asia Congress (ESMO Asia 2024) was held in Singapore from December 6 to 8. In the session featuring selected oral presentations on thoracic oncology, Professor Wentao Fang from Shanghai East Hospital, Tongji University presented findings from the AL3810-202 trial (Abstract 625O), which evaluated Lucitanib (Delitinib, AL3810) as a…
Connecting Medical Expertise through Media